Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce .
Amarin Corporation plcMarch 17, 2021 GMT
28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk
Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups
Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction
REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Award to recognize the authors with the highest ranked abstract from the United States at the International Stroke Conference 2021
Switzerland
United-states
New-jersey
Lebanon
Boston
Massachusetts
Ireland
United-arab-emirates
Canada
Dublin
American
Clin-cardiol